U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. (Treatment Improvement Protocol (TIP) Series, No. 40.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.

Show details

Appendix A. Bibliography

  1. Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate‐day buprenorphine dosing is preferred to daily dosing by opioid‐dependent humans. Psychopharmacology. 1998;136(3):217–225. [PubMed: 9566806]
  2. Amass L., Bickel W.K., Higgins S.T., Badger G.J. Alternate‐day dosing during buprenorphine treatment of opioid dependence. Life Sciences. 1994a;54(17):1215–1228. [PubMed: 8164503]
  3. Amass L., Bickel W.K., Higgins S.T., Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases. 1994b;13(3):33–45. [PubMed: 7734458]
  4. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate‐day dosing regimens with the combination buprenorphine‐naloxone tablet. Drug and Alcohol Dependence. 2000;58(1–2):143–152. [PubMed: 10669065]
  5. Amass L., Kamien J.B., Mikulich S.K. Thrice‐weekly supervised dosing with the combination buprenorphine‐naloxone tablet is preferred to daily supervised dosing by opioid‐dependent humans. Drug and Alcohol Dependence. 2001;61(2):173–181. [PubMed: 11137282]
  6. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998 Jun;101(6):1079–1088. Erratum in: Pediatrics 102(3 Pt 1):660; 1998. http://www​.aap.org/policy/re9746.html [Accessed June 9, 2004]. [PubMed: 9614425]
  7. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM‐IV‐TR). Washington, DC: American Psychiatric Association, 2000.
  8. Angres, D.H.; Talbott, G.D.; and Bettinardi‐Angres, K. Healing the Healer: The Addicted Physician. Madison, CT: Psychosocial Press, 1998.
  9. Anthony, J.C., and Helzer, J.E. Syndromes of drug use and dependence. In: Robins, L.N., and Regier, D.A., eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press, 1991.
  10. Armenian S.H., Chutuape M.A., Stitzer M.L. Predictors of discharges against medical advice from a short‐term hospital detoxification unit. Drug and Alcohol Dependence. 1999;56(1):1–8. [PubMed: 10462086]
  11. Babor, T.F.; Higgins‐Biddle, J.C.; Saunders, J.B.; and Monteiro, M.G. The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care, 2nd ed. Geneva: World Health Organization, 2001. http://www​.who.int/substance_abuse​/publications/alcohol/en or http://whqlibdoc​.who​.int/hq/2001/WHO_MSD_MSB_01.6a.pdf [Accessed June 9, 2004].
  12. Banys P., Clark H.W., Tusel D.J., Sees K., Stewart P., Mongan L., Delucchi K., Callaway E. An open trial of low dose buprenorphine in treating methadone withdrawal. Journal of Substance Abuse Treatment. 1994;11(1):9–15. [PubMed: 8201637]
  13. Barnett P.G., Rodgers J.H., Bloch D.A. A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96(5):683–690. [PubMed: 11331027]
  14. Berson A., Gervais A., Cazals D., Boyer N., Durand F., Bernuau J., Marcellin P., Degott C., Valla D., Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. Journal of Hepatology. 2001;34(2):346–350. [PubMed: 11281569]
  15. Bickel W.K., Amass L., Crean J.P., Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid‐dependent patients. Psychopharmacology. 1999;146(2):111–118. [PubMed: 10525745]
  16. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics. 1988a;43(1):72–78. [PubMed: 3275523]
  17. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: Dose‐related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology and Experimental Therapeutics. 1988b;247(1):47–53. [PubMed: 2459370]
  18. Bradley B.P., Gossop M., Phillips G.T., Legarda J.J. The development of an opiate withdrawal scale (OWS). British Journal of Addiction. 1987;82(10):1139–1142. [PubMed: 3479162]
  19. Bradley K.A., Boyd‐Wickizer J., Powell S.H., Burman M.L. Alcohol screening questionnaires in women: A critical review. Journal of the American Medical Association. 1998;280(2):166–171. [PubMed: 9669791]
  20. Brewster D., Humphrey M.J., Mcleavy M.A. The systemic bioavailability of buprenorphine by various routes of administration. Journal of Pharmacy and Pharmacology. 1981;33(8):500–506. [PubMed: 6115924]
  21. Brooks, M.K. Legal and ethical issues. In: Center for Substance Abuse Treatment. A Guide to Substance Abuse Services for Primary Care Clinicians. Treatment Improvement Protocol (TIP) Series, Number 24. DHHS Pub. No. (SMA) 97‐3139. Washington, DC: U.S. Government Printing Office, 1997. pp. 103–114. http://www​.kap.samhsa​.gov/products/manuals/index.htm [Accessed July 29, 2004].
  22. Brooner R.K., King V.L., Kidorf M., Schmidt Jr. C.W., Bigelow G.E. Psychiatric and substance use comorbidity among treatment‐seeking opioid abusers. Archives of General Psychiatry. 1997;54(1):71–80. [PubMed: 9006403]
  23. Brown R.L. , and Rounds, L.A. Conjoint screening questionnaires for alcohol and other drug abuse: Criterion validity in a primary care practice. Wisconsin Medical Journal. 1995;94(3):135–140. [PubMed: 7778330]
  24. Brownell K.D., Marlatt G.A., Lichtenstein E., Wilson G.T. Understanding and preventing relapse. American Psychologist. 1986;41(7):765–782. [PubMed: 3527003]
  25. Burge, S.K., and Schneider, F.D. Alcohol‐related problems: Recognition and intervention. American Family Physician 59(2):361–370, 372, 1999. http://www​.aafp.org/afp/990115ap/361​.html [Accessed June 9, 2004]. [PubMed: 9930129]
  26. Busto U.E., Sykora K., Sellers E.M. A clinical scale to assess benzodiazepine withdrawal. Journal of Clinical Psychopharmacology. 1989;9(6):412–416. [PubMed: 2574193]
  27. Carrieri M.P., Vlahov D., Dellamonica P., Gallais H., Lepeu G., Spire B., Obadia Y. Use of buprenorphine in HIV‐infected injection drug users: Negligible impact on virologic response to HAART. The Manif‐2000 Study Group. Drug and Alcohol Dependence. 2000;60(1):51–54. [PubMed: 10821989]
  28. Casavant M.J. Urine drug screening in adolescents. Pediatric Clinics of North America. 2002;49(2):317–327. [PubMed: 11993285]
  29. Center for Substance Abuse Treatment. Medication‐Assisted Treatment for Opioid Addiction. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development. [PubMed: 22514849]
  30. Center for Substance Abuse Treatment (CSAT). A Guide to Substance Abuse Services for Primary Care Clinicians. Treatment Improvement Protocol (TIP) Series, Number 24. DHHS Pub. No. (SMA) 97‐3139. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997. http://www​.kap.samhsa​.gov/products/manuals/index.htm [Accessed July 9, 2004]. [PubMed: 22514830]
  31. Center for Substance Abuse Treatment (CSAT). Brief Interventions and Brief Therapies for Substance Abuse. Treatment Improvement Protocol (TIP) Series, Number 34. DHHS Pub. No. (SMA) 99‐3353. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999a. http://www​.kap.samhsa​.gov/products/manuals/index.htm [Accessed July 29, 2004].
  32. Center for Substance Abuse Treatment (CSAT). Enhancing Motivation for Change in Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series, Number 35. DHHS Pub. No. (SMA) 99‐3354. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999b. http://www​.kap.samhsa​.gov/products/manuals/index.htm [Accessed July 29, 2004]. [PubMed: 22514841]
  33. Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2001. Atlanta, GA: U.S. Department of Health and Human Services, CDC, September 2002. http://www​.cdc.gov/nchstp​/tb/surv/surv2001/default.htm. See tables 28, 29, and 30 [Accessed July 29, 2004].
  34. Chan A.W.K., Pristach E.A., Welte J.W., Russell M. Use of the TWEAK test in screening for alcoholism/heavy drinking in three populations. Alcoholism Clinical and Experimental Research. 1993;17(6):1188–1192. [PubMed: 8116829]
  35. Cherubin C.E. , and Sapira, J.D. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Annals of Internal Medicine. 1993;119(10):1017–1028. [PubMed: 8214979]
  36. Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence. 1994;36(2):115–121. [PubMed: 7851278]
  37. Chowdhury A.N. , and Chowdhury, S. Buprenorphine abuse: Report from India. British Journal of Addiction. 1990;85(10):1349–1350. [PubMed: 2265296]
  38. Clark H.W. Office‐based practice and opioid‐use disorders. New England Journal of Medicine. 2003;349(10):928–930. [PubMed: 12954740]
  39. Comer S.D., Collins E.D., Fischman M.W. Buprenorphine sublingual tablets: Effects on IV heroin self‐administration by humans. Psychopharmacology. 2001;154(1):28–37. [PubMed: 11292003]
  40. Cowan A., Doxey J.C., Harry E.J. The animal pharmacology of buprenorphine, an oripavine analgesic agent. British Journal of Pharmacology. 1977;60(4):547–554. [PMC free article: PMC1667382] [PubMed: 409449]
  41. Crane, E. Narcotic Analgesics. The Drug Abuse Warning Network (DAWN) Report. January 2003. Available at http://oas​.samhsa.gov/2k3/pain/DAWNpain​.pdf [Accessed June 9, 2004].
  42. DiClemente, C.C., and Prochaska, J.O. Toward a comprehensive transtheoretical model of change: Stages of change and addictive behaviors. In: Miller, W.R., and Heather, N., eds. Treating Addictive Behaviors, 2nd ed. New York: Plenum Press, 1998. pp. 3–24.
  43. DiClemente, C.C., and Scott, C.W. Stages of change: Interactions with treatment compliance and involvement. In: Onken, L.S.; Blaine, J.D.; and Boren, J.J., eds. Beyond the Therapeutic Alliance: Keeping the Drug‐Dependent Individual in Treatment. NIDA Research Monograph Series, Number 165. DHHS Pub. No. (ADM) 97‐4142. Rockville, MD: National Institute on Drug Abuse, 1997. pp. 131–156. [PubMed: 9243549]
  44. DiPaula B.A., Schwartz R., Montoya I.D., Barrett D., Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. Journal of Substance Abuse Treatment. 2002;23(3):163–169. [PMC free article: PMC2633653] [PubMed: 12392802]
  45. Doxey, J.C.; Everitt, J.E.; Frank, L.W.; and MacKenzie, J.E. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. British Journal of Pharmacology 75(S):118P, 1982 (Abstract).
  46. Drug Abuse Treatment Outcome Studies (DATOS). National Institute on Drug Abuse (NIDA). http://www​.drugabuse​.gov/about/organization/despr/DATOS.html [Accessed June 9, 2004].
  47. Drug Addiction Treatment Act of 2000. Public Law No. 106‐310, Title XXXV─Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment, 2000. http://www​.buprenorphine​.samhsa.gov/fulllaw.html [Accessed June 9, 2004].
  48. Edwards G., Orford J., Egert S., Guthrie S., Hawker A., Hensman C., Mitcheson M., Oppenheimer E., Taylor C. Alcoholism: A controlled trial of "treatment" and "advice. " Journal of Studies on Alcohol. 1977;38(5):1004–1031. [PubMed: 881837]
  49. Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., Stitzer M.L. Buprenorphine's physical dependence potential: Antagonist‐precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics. 1996;276(2):449–459. [PubMed: 8632309]
  50. Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., Stitzer M.L. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine‐maintained patients. Drug and Alcohol Dependence. 1997;45(1–2):81–91. [PubMed: 9179510]
  51. Elvy G.A., Wells J.E., Baird K.A. Attempted referral as intervention for problem drinking in the general hospital. British Journal of Addiction. 1988;83(1):83–89. [PubMed: 3345386]
  52. Fiellin D.A. , and O'Connor, P.G. Clinical practice. Office‐based treatment of opioid‐dependent patients. New England Journal of Medicine. 2002;347(11):817–823. [PubMed: 12226153]
  53. Fiellin D.A., Rosenheck R.A., Kosten T.R. Office‐based treatment for opioid dependence: Reaching new patient populations. American Journal of Psychiatry. 2001;158(8):1200–1204. [PubMed: 11481150]
  54. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid‐dependent pregnant women with buprenorphine. Addiction. 2000;95(2):239–244. [PubMed: 10723852]
  55. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., Tusel D. Buprenorphine/Naloxone Collaborative Study Group. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine. 2003;349(10):949–958. [PubMed: 12954743]
  56. Fultz J.M. , and Senay, E.C. Guidelines for the management of hospitalized narcotics addicts. Annals of Internal Medicine. 1975;82(6):815–818. [PubMed: 1138596]
  57. Gal T.J. Naloxone reversal of buprenorphine‐induced respiratory depression. Clinical Pharmacology and Therapeutics. 1989;45(1):66–71. [PubMed: 2491980]
  58. Gaulier J.M., Marquet P., Lacassie E., Dupuy J.L., Lachatre G. Fatal intoxication following self‐administration of a massive dose of buprenorphine. Journal of Forensic Sciences. 2000;45(1):226–228. [PubMed: 10641946]
  59. Goldstein, A. Addiction: From Biology to Drug Policy. New York: W.H. Freeman, 1994.
  60. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors. 1990;15(5):487–490. [PubMed: 2248123]
  61. Gourlay, D.; Heit, H.; and Caplan, Y. Sponsor: California Academy of Family Physicians. Urine Drug Testing in Primary Care: Dispelling the Myths & Designing Strategies, 2002. http://www​.alaskaafp.org/udt.pdf [Accessed June 9, 2004].
  62. Gray R.F., Ferry A., Jauhar P. Emergence of buprenorphine dependence. British Journal of Addiction. 1989;84(11):1373–1374. [PubMed: 2597815]
  63. Hammett‐Stabler C.A., Pesce A.J., Cannon D.J. Urine drug screening in the medical setting. Clinica Chimica Acta. 2002;315(1–2):125–135. [PubMed: 11728415]
  64. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., Kanof P.D. Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse. 1987;13(3):293–308. [PubMed: 3687892]
  65. Harris D.S., Jones R.T., Welm S., Upton R.A., Lin E., Mendelson J. Buprenorphine and naloxone co‐administration in opiate‐dependent patients stabilized on sublingual buprenorphine. Drug and Alcohol Dependence. 2000;61(1):85–94. [PubMed: 11064186]
  66. Heather, N.; Robertson, I.; MacPherson, B.; Allsop, S.; and Fulton, A. Effectiveness of a controlled drinking self‐help manual: One‐year follow‐up results. British Journal of Clinical Psychology 26(Pt. 4):279–287, 1987. [PubMed: 3427250]
  67. Hoffmann, N.G., and Harrison, P.A. SUDDS‐IV: Substance Use Disorder Diagnostic Schedule. Smithfield, RI: Evince Clinical Assessments, 2002. http://www​.evinceassessment​.com/product_sudds.html [Assessed June 9, 2004].
  68. Ibrahim R.B., Wilson J.G., Thorsby M.E., Edwards D.J. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sciences. 2000;66(14):1293–1298. [PubMed: 10755464]
  69. International Classification of Diseases, 9th Rev., Clinical Modification: ICD‐9‐CM. Volumes 1 and 2. Salt Lake City, UT: http://www.cdc.gov/nchstp/tb/surv/surv2001/default.htm Ingenix, Medicode, 2003. 810 pages.
  70. Iribarne C., Picart D., Dreano Y., Bail J.P., Berthou F. Involvement of cytochrome P450 3A4 in N‐dealkylation of buprenorphine in human liver microsomes. Life Sciences. 1997;60(22):1953–1964. [PubMed: 9180349]
  71. Jacox, A.; Carr, D.B.; Payne, R.; Berde, C.B.; Breitbart, W.; Cain, J.M.; Chapman, C.R.; Cleeland, C.S.; Ferrell, B.R.; Finley, R.S.; Hester, N.O.; Hill Jr., C.S.; Leak, W.D.; Lipman, A.G.; Logan, C.L.; McGarvey, C.L.; Miaskowski, C.A.; Mulder, D.S.; Paice, J.A.; Shapiro, B.S.; Silberstin, E.B.; Smith, R.S.; Stover, J.; Tsou, C.V.; Vecchiarelli, L.; and Weissman, D.E. Management of cancer pain. Clinical practice guideline No. 9. AHCPR Pub. No. 94‐0592. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, March 1994.
  72. Jasinski D.R., Fudala P.J., Johnson R.E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clinical Pharmacology and Therapeutics. 1989;45(5):513–519. [PubMed: 2721107]
  73. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry. 1978;35(4):501–516. [PubMed: 215096]
  74. Johnson, R.E.; Chutuape, M.A.; Strain, E.C.; Walsh, S.L.; Stitzer, M.L.; and Bigelow, G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343(18):1290–1297, 2000. http://www​.mja.com.au​/public/issues/176_10_200502​/gow10037_fm.html [Accessed June 9, 2004]. [PubMed: 11058673]
  75. Johnson R.E., Cone E.J., Henningfield J.E., Fudala P.J. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clinical and Pharmacology Therapeutics. 1989;46(3):335–343. [PubMed: 2776393]
  76. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence. 1995;40(1):17–25. [PubMed: 8746920]
  77. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association. 1992;267(20):2750–2755. [PubMed: 1578593]
  78. Johnson R.E., Jones H.E., Fischer G. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. Drug and Alcohol Dependence. 2003a;70(2 Suppl):S87–S101. [PubMed: 12738353]
  79. Johnson R.E., Strain E.C., Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence. 2003b;70(2 Suppl):S59–S77. [PubMed: 12738351]
  80. Kilicarslan T. , and Sellers, E.M. Lack of interaction of buprenorphine with flunitrazepam metabolism. American Journal of Psychiatry. 2000;157(7):1164–1166. [PubMed: 10873929]
  81. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., Kuroiwa Y. Human buprenorphine N‐dealkylation is catalyzed by cytochrome P450 3A4. Drug Metabolism and Disposition. 1998;26(8):818–821. [PubMed: 9698298]
  82. Kuhlman Jr. J.J., Lalani S., Magluilo Jr. J., Levine B., Darwin W.D. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. Journal of Analytical Toxicology. 1996;20(6):369–378. [PubMed: 8889672]
  83. Lange W.R., Fudala P.J., Dax E.M., Johnson R.E. Safety and side‐effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependence. 1990;26(1):19–28. [PubMed: 2209411]
  84. Lejeune C., Aubisson S., Simmat‐Durand L., Cneude F., Piquet M., Gourarier L. ; and le Groupe d'Etudes Grossesse et addictions. Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high‐dose buprenorphine: 246 cases. Annales de Medecine Interne (Paris). 2001;152 Suppl 7:21–27. [PubMed: 11965095]
  85. Ling W., Charuvastra C., Collins J.F., Batki S., Brown Jr. L.S., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner Jr. J.A., Santos E., Casadonte P., Fye C., Stine S., Wang R.I., Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction. 1998;93(4):475–486. [PubMed: 9684386]
  86. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry. 1996;53(5):401–407. [PubMed: 8624183]
  87. Lloyd‐Jones J.G., Robinson P., Henson R., Biggs S.R., Taylor T. Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. European Journal of Drug Metabolism and Pharmacokinetics. 1980;5(4):233–239. [PubMed: 7250147]
  88. Lopez, F. Confidentiality of Patient Records for Alcohol and Other Drug Treatment. Technical Assistance Publication (TAP) Series, Number 13. DHHS Pub. No. (SMA) 95‐3018. Rockville, MD: Center for Substance Abuse Treatment, 1994.
  89. Loustauneau, A.; Auriacombe, M.; Daulouede, J.P.; and Tignol, J. Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature. Annales de Medecine Interne (Paris) 153(7 Suppl):2S31–2S36, 2002. [PubMed: 12518080]
  90. Maisto S.A. , and Saitz, R. Alcohol use disorders: Screening and diagnosis. American Journal of Addictions. 2003;12(Suppl 1):S12–S25. [PubMed: 14972777]
  91. Marlatt, G.A., and Gordon, J.R., eds. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press, 1985.
  92. Marquet P., Chevrel J., Lavignasse P., Merle L., Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clinical Pharmacology and Therapeutics. 1997;62(5):569–571. [PubMed: 9390114]
  93. McCance‐Katz E.F., Rainey P.M., Friedland G., Kosten T.R., Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. American Journal on Addictions. 2001;10(4):296–307. [PubMed: 11783744]
  94. McConnaughy E.A., Prochaska J.O., Velicer W.F. Stages of change in psychotherapy: Measurement and sample profiles. Psychotherapy: Theory/Research/Practice/Training. 1983;20:368–375.
  95. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association. 1993;269(15):1953–1959. [PubMed: 8385230]
  96. McLellan, A.T.; Kushner, H.; Metzger, D.; Peters, R.; Smith, I.; Grissom, G.; Pettinati, H.; and Argeriou, M. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9(3):199–213, 1992. http://www​.tresearch.org [Accessed June 9, 2004]. [PubMed: 1334156]
  97. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168(1):26–33. [PubMed: 7351540]
  98. Mee‐Lee, D. An instrument for treatment progress and matching: The Recovery Attitude and Treatment Evaluator (RAATE). Journal of Substance Abuse Treatment 5(3):183–186, 1988. http://www​.niaaa.nih​.gov/publications/raate.htm [Accessed June 9, 2004]. [PubMed: 3236391]
  99. Mee‐Lee, D., ed. American Society of Addiction Medicine Patient Placement Criteria for the Treatment of Substance‐Related Disorders, 2nd ed.—Revised (PPC‐2R). Chevy Chase, MD: American Society of Addiction Medicine, 2001. http://www​.asam.org [Accessed June 9, 2004].
  100. Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self‐administration: An operant analysis. Journal of Pharmacology and Experimental Therapeutics. 1982;223(1):30–39. [PubMed: 7120124]
  101. Metzger D., Woody G.E., De Philippis D., McLellan A.T., O'Brien C.P., Platt J.J. Risk factors for needle sharing among methadone‐treated patients. American Journal of Psychiatry. 1991;148(5):636–640. [PubMed: 2018166]
  102. Metzger D.S., Woody G., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in‐ and out‐of‐treatment: An 18‐month prospective follow‐up. Journal of Acquired Immune Deficiency Syndrome. 1993;6(9):1049–1056. [PubMed: 8340896]
  103. Miller W.R. Motivation for treatment: A review with special emphasis on alcoholism. Psychological Bulletin. 1985;98(1):84–107. [PubMed: 3898175]
  104. Miller W.R., Benefield R.G., Tonigan J.S. Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles. Journal of Consulting and Clinical Psychology. 1993;61(3):455–461. [PubMed: 8326047]
  105. Miller, W.R., and Rollnick, S. Motivational Interviewing: Preparing People to Change Addictive Behavior, 2nd ed. New York Guilford Press, 1991.
  106. Miller, W.R., and Sanchez, V.C. Motivating young adults for treatment and lifestyle change. In: Howard, G.S., and Nathan, P.E., eds. Alcohol Use and Misuse by Young Adults. Notre Dame, IN: University of Notre Dame Press, 1994.
  107. Miller, W.R., and Tonigan, J.S. Assessing drinkers' motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychology of Addictive Behaviors 10(2):81–89, 1996. http://casaa​.unm.edu/inst/inst.html [Accessed June 9, 2004].
  108. Moatti J.P., Carrieri M.P., Spire B., Gastaut J.A., Cassuto J.P., Moreau J. Adherence to HAART in French HIV‐infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS. 2000;14(2):151–155. [PubMed: 10708285]
  109. Morrison V. Psychoactive substance use and related behaviours of 135 regular illicit drug users in Scotland. Drug and Alcohol Dependence. 1989;23(2):95–101. [PubMed: 2702930]
  110. Najavits L.M. , and Weiss, R.D. Variations in therapist effectiveness in the treatment of patients with substance use disorders: An empirical review. Addiction. 1994;89(6):679–688. [PubMed: 8069169]
  111. Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., Mendelson J.E. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations. Journal of Clinical Pharmacology. 1999;39(6):619–623. [PubMed: 10354966]
  112. National Center on Addiction and Substance Abuse (CASA) at Columbia University. Missed Opportunity: National Survey of Primary Care Physicians and Patients on Substance Abuse. New York: CASA Publications, 2000. http://www​.casacolumbia​.org/pdshopprov/shop/ [Accessed July 29, 2004].
  113. National Institutes of Health (NIH). Effective Treatment of Opiate Addiction. Consensus Statement Nov 17–19. 1997;15(6):4.
  114. Nelson, J.E.; Pearson, H.W.; Sayers, M.; and Glynn, T.J. Research issues 26: Guide to drug abuse research terminology. Pub. No. ADM 82‐1237. Rockville, MD: National Institute on Drug Abuse, Public Health Service, U.S. Department of Health and Human Services, 1982.
  115. Nigam A.K., Ray R., Tripathi B.M. Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment. 1993;10(4):391–394. [PubMed: 8257551]
  116. Nikoda, V.V.; Lebedeva, R.N.; Artamoshina, M.P.; and Storozhenko, I.N. Comparative evaluation of the use of nalbuphine and buprenorphine in prehospital care. Anesteziologiya I Reanimatologiya (5):23–28, 1998. [PubMed: 9866242]
  117. Obadia Y., Perrin V., Feroni I., Vlahov D., Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96(2):267–272. [PubMed: 11182872]
  118. O'Connor J.J., Moloney E., Travers R., Campbell A. Buprenorphine abuse among opiate addicts. British Journal of Addiction. 1988;83(9):1085–1087. [PubMed: 3265643]
  119. O'Connor P.G. , and Fiellin, D.A. Pharmacologic treatment of heroin‐dependent patients. Annals of Internal Medicine. 2000;133(1):40–54. [PubMed: 10877739]
  120. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E., Carroll K.M., Kosten T.R., Rounsaville B.J. A pilot study of primary‐care‐based buprenorphine maintenance for heroin dependence. American Journal of Drug and Alcohol Abuse. 1996;22(4):523–531. [PubMed: 8911590]
  121. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E., Carroll K.M., Kosten T.R., Rounsaville B.J., Pakes J.A., Schottenfeld R.S. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine. 1998;105(2):100–105. [PubMed: 9727815]
  122. Office of National Drug Control Policy (ONDCP). Drug Policy Information Clearinghouse. Heroin Fact Sheet June 2003. http://www​.whitehousedrugpolicy​.gov/publications​/factsht/heroin/197335.pdf [Accessed June 9, 2004].
  123. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence. 2000;60(1):39–50. [PubMed: 10821988]
  124. Parran T.V., Adelman C.L., Jasinski D.R. A buprenorphine stabilization and rapid‐taper protocol for the detoxification of opioid‐dependent patients. American Journal on Addictions. 1994;3(4):306–331.
  125. Peachey J.E. , and Lei, H. Assessment of opioid dependence with naloxone. British Journal of Addiction. 1988;83(2):193–201. [PubMed: 3345396]
  126. Perez de los Cobos J., Martin S., Etcheberrigaray A., Trujols J., Batlle F., Tejero A., Queralto J.M., Casas M. A controlled trial of daily versus thrice‐weekly buprenorphine administration for the treatment of opioid dependence. Drug and Alcohol Dependence. 2000;59(3):223–233. [PubMed: 10812283]
  127. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., Ladewig D. Double‐blind randomized trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence. 2001;62(1):97–104. [PubMed: 11173173]
  128. Petry N.M., Bickel W.K., Badger G.J. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clinical Pharmacology and Therapeutics. 1999;66(3):306–314. [PubMed: 10511067]
  129. Petry N.M., Bickel W.K., Piasecki D., Marsch L.A., Badger G.J. Elevated liver enzyme levels in opioid‐dependent patients with hepatitis treated with buprenorphine. American Journal on Addictions. 2000;9(3):265–269. [PubMed: 11000922]
  130. Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clinical Pharmacology and Therapeutics. 1993;53(5):570–576. [PubMed: 8491067]
  131. Preston K.L., Bigelow G.E., Liebson I.A. Effects of sublingually given naloxone in opioid‐dependent human volunteers. Drug and Alcohol Dependence. 1990;25(1):27–34. [PubMed: 2323306]
  132. Preston K.L., Umbricht A., Epstein D.H. Abstinence reinforcement maintenance contingency and one‐year follow‐up. Drug and Alcohol Dependence. 2002;67(2):125–137. [PubMed: 12095662]
  133. Prochaska J.O. , and DiClemente, C.C. Stages of change in the modification of problem behaviors. Progress in Behavior Modification. 1992;28:183–218. [PubMed: 1620663]
  134. Prochaska, J.O.; DiClemente, C.C.; and Norcross J.C. In search of the structure of change. In: Klar, Y.; Fisher, J.D.; Chinsky, J.M.; and Nadler, A., eds. Self‐Change: Social, Psychological, and Clinical Perspectives. New York: Springer‐Verlag, 1992. pp. 87–114.
  135. Reckitt Benckiser Healthcare (UK), Ltd. and Reckitt Benckiser Pharmaceuticals, Inc. (2002). Subutex® (buprenorphine hydrochloride) and Suboxone® tablets (buprenorphine hydrochloride and naloxone hydrochloride). [drug label]. http://www​.fda.gov/cder​/foi/label/2002/20732lbl.pdf. [Accessed June 9, 2004].
  136. Reynaud M., Petit G., Potard D., Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998a;93(9):1385–1392. [PubMed: 9926544]
  137. Reynaud M., Tracqui A., Petit G., Potard D., Courty P. Six deaths linked to misuse of buprenorphine‐benzodiazepine combinations. American Journal of Psychiatry. 1998b;155(3):448–449. [PubMed: 9501765]
  138. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine‐naloxone combination in Wellington, New Zealand. Drug and Alcohol Dependence. 1993;33(1):81–86. [PubMed: 8370341]
  139. Rollnick S., Heather N., Gold R., Hall W. Development of a short "readiness to change" questionnaire for use in brief, opportunistic interventions among excessive drinkers. British Journal of Addiction. 1992;87(5):743–754. [PubMed: 1591525]
  140. Rosen M.I., Wallace E.A., McMahon T.J., Pearsall H.R., Woods S.W., Price L.H., Kosten T.R. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug and Alcohol Dependence. 1994;35(2):141–149. [PubMed: 7519977]
  141. Rounsaville B.J., Weissman M.M., Kleber H., Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Archives of General Psychiatry. 1982;39(2):161–168. [PubMed: 7065830]
  142. Russell M., Martier S.S., Sokol R.J., Jacobson S., Jacobson J., Bottoms S. Screening for pregnancy risk drinking: TWEAKING the tests. Alcoholism Clinical and Experimental Research. 1991;15(2):638. [PubMed: 7847599]
  143. Saitz, R. Overview of medical and surgical complications of addiction. In: Graham, A.W.; Schultz, T.K.; Mayo‐Smith, M.F.; Ries, R.K.; and Wilford, B.B., eds. Principles of Addiction Medicine, 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. http://www​.asam.org [Accessed June 9, 2004].
  144. Sakol M.S., Stark C., Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow─an increase. British Journal of Addiction. 1989;84(4):439–441. [PubMed: 2566343]
  145. San L., Cami J., Fernandez T., Ollé J.M., Peri J.M., Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine‐dependent subjects. British Journal of Addiction. 1992;87(1):55–62. [PubMed: 1311974]
  146. Schottenfeld R.S., Pakes J., O'Connor P., Chawarski M., Oliveto A., Kosten T.R. Thrice‐weekly versus daily buprenorphine maintenance. Biological Psychiatry. 2000;47(12):1072–1079. [PubMed: 10862807]
  147. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry. 1997;54(8):713–720. [PubMed: 9283506]
  148. Schuh K.J. , and Johanson, C.E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug and Alcohol Dependence. 1999;56(1):55–60. [PubMed: 10462093]
  149. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., Banys P., Hall S.M. Methadone maintenance vs 180‐day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. Journal of the Americam Medical Association. 2000;283(10):1303–1310. [PubMed: 10714729]
  150. Selzer, M.L. The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. American Journal of Psychiatry 127(12):1653–1658, 1971. http://ajp​.psychiatryonline.org [Accessed June 9, 2004]. http://www​.niaaa.nih​.gov/publications/mast.htm [Accessed June 9, 2004]. [PubMed: 5565851]
  151. Selzer M.L., Vinokur A., van Rooijen L. A self‐administered Short Michigan Alcoholism Screening Test (SMAST). Journal of Studies on Alcohol. 1975;36(1):117–126. [PubMed: 238068]
  152. Senay E.C., Dorus W., Goldberg F., Thornton W. Withdrawal from methadone maintenance. Rate of withdrawal and expectation. Archives of General Psychiatry. 1977;34(3):361–367. [PubMed: 843188]
  153. Simpson, D.D., and Sells, S.B. Opioid Addiction and Treatment: A 12‐Year Follow‐up. Malabar, FL: Krieger Publishing, 1989.
  154. Singh R.A., Mattoo S.K., Malhotra A., Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica. 1992;86(1):46–48. [PubMed: 1414399]
  155. Skinner, H.A. The drug abuse screening test. Addictive Behaviors 7(4):363–371, 1982. http://www​.nida.nih.gov​/Diagnosis‐Treatment/DAST10​.html [Accessed June 9, 2004]. [PubMed: 7183189]
  156. Skinner H.A., Holt S., Schuller R., Roy J., Israel Y. Identification of alcohol abuse using laboratory tests and a history of trauma. Annals of Internal Medicine. 1984;101(6):847–851. [PubMed: 6149716]
  157. Stein M.D. Medical complications of intravenous drug use. Journal of General Internal Medicine. 1990;5(3):249–257. [PubMed: 2187962]
  158. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid‐dependent humans. Psychopharmacology. 2001;154(3):230–242. [PubMed: 11351930]
  159. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone‐maintained volunteers. Journal of Pharmacology and Experimental Therapeutics. 1992;261(3):985–993. [PubMed: 1376362]
  160. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone‐maintained volunteers: Effects at two hours after methadone. Journal of Pharmacology and Experimental Therapeutics. 1995;272(2):628–638. [PubMed: 7853176]
  161. Strain, E.C., and Stitzer, M.L., eds. Methadone treatment for opioid dependence. Baltimore, MD: Johns Hopkins University Press, 1999.
  162. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid‐dependent cocaine users. Psychopharmacology. 1994a;116(4):401–406. [PubMed: 7701040]
  163. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry. 1994b;151(7):1025–1030. [PubMed: 8010359]
  164. Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non‐dependent opioid abusers. Psychopharmacology. 2000;148(4):374–383. [PubMed: 10928310]
  165. Strain E.C., Walsh S.L., Bigelow G.E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology. 2002;159(2):161–166. [PubMed: 11862344]
  166. Strang J. Abuse of buprenorphine. Lancet. 1985;2(8457):725. [PubMed: 2863704]
  167. Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Pharmacologic Therapies. Unpublished data, 2002a.
  168. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Emergency Department Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2002. DAWN Series: D‐22, DHHS Pub. No. (SMA) 03‐3779. Rockville, MD, 2002b. http://dawninfo​.samhsa​.gov/pubs_94_02/edpubs/default.asp [Accessed June 9, 2004].
  169. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Mortality Data From the Drug Abuse Warning Network, 2001. DAWN Series D‐23, DHHS Pub. No. (SMA) 03‐3781. Rockville, MD, 2002c. http://dawninfo​.samhsa​.gov/pubs_94_02/mepubs/default.asp [Accessed June 9, 2004].
  170. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C., Sellers E.M. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment For Alcohol Scale (CIWA‐Ar). British Journal of Addiction. 1989;84(11):1353–1357. [PubMed: 2597811]
  171. Talbott G.D., Gallegos K.V., Wilson P.O., Porter T.L. The Medical Association of Georgia's Impaired Physicians Program. Review of the first 1000 physicians: Analysis of specialty. Journal of the American Medical Association. 1987;257(21):2927–2930. [PubMed: 3573291]
  172. Therapeutic Communities of America (TCA). http://www​.therapeuticcommunitiesofamerica.org [Accessed June 9, 2004].
  173. Thörn S.E., Rawal N., Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet. 1988;1(8578):179–180. [PubMed: 2893012]
  174. Title 42, Part 2 of the Code of Federal Regulations (42 C.F.R., Part 2), 2001. http://www​.access.gpo​.gov/cgi‐bin/cfrassemble​.cgi?title=200142 [Accessed June 9, 2004].
  175. Tracqui A., Kintz P., Ludes B. Buprenorphine‐related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytical Toxicology. 1998;22(6):430–434. [PubMed: 9788517]
  176. Vignau J. Preliminary assessment of a 10‐day rapid detoxification programme using high dosage buprenorphine. European Addiction Research. 1998;4(Suppl. 1):29–31. [PubMed: 9767204]
  177. Walsh S.L., June H.L., Schuh K.J., Preston K.L., Bigelow G.E., Stitzer M.L. Effects of buprenorphine and methadone in methadone‐maintained subjects. Psychopharmacology. 1995;119(3):268–276. [PubMed: 7675960]
  178. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics. 1994;55(5):569–580. [PubMed: 8181201]
  179. Walter, D., and Inturrisi, C. Absorption, Distribution, Metabolism, and Excretion of Buprenorphine in Animals and Humans. In: Cowan, A., and Lewis, J.W., eds. Buprenorphine: Combatting Drug Abuse With a Unique Opioid. New York: Wiley‐Liss, 1995.
  180. Weinberg D.S., Inturrisi C.E., Reidenberg B., Moulin D.E., Nip T.J., Wallenstein S., Houde R.W., Foley K.M. Sublingual absorption of selected opioid analgesics. Clinical Pharmacology and Therapeutics. 1988;44(3):335–342. [PubMed: 2458208]
  181. Wesson, D.; Ling, W.; and Jara, G. Buprenorphine in Pharmacotherapy of Opioid Addiction: Implementation in Office‐Based Medical Practice. Translating the Experience of Clinical Trials into Clinical Practice. San Francisco, CA: California Society of Addiction Medicine, 1999.


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.1M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...